Pharmacokinetics-Pharmacodynamics of Gatifloxacin in a Lethal Murine Bacillus anthracis Inhalation Infection Model
Authors:
- 1 December 2007
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 51 (12) , 4351-4355
Abstract
We determined the pharmacokinetic-pharmacodynamic (PK-PD) measure most predictive of gatifloxacin efficacy and the magnitude of this measure necessary for survival in a murine Bacillus anthracis inhalation infection model. We then used population pharmacokinetic models for gatifloxacin and simulation to identify dosing regimens with high probabilities of attaining exposures likely to be efficacious in adults and children. In this work, 6- to 8-week-old nonneutropenic female BALB/c mice received aerosol challenges of 50 to 75 50% lethal doses of B. anthracis (Ames strain, for which the gatifloxacin MIC is 0.125 mg/liter). Gatifloxacin was administered at 6- or 8-h intervals beginning 24 h postchallenge for 21 days, and dosing was designed to produce profiles mimicking fractionated concentration-time profiles for humans. Mice were evaluated daily for survival. Hill-type models were fitted to survival data. To identify potentially effective dosing regimens, adult and pediatric population pharmacokinetic models for gatifloxacin and Monte Carlo simulation were used to generate 5,000 individual patient exposure estimates. The ratio of the area under the concentration-time curve from 0 to 24 h (AUC 0-24 ) to the MIC of the drug for the organism (AUC 0-24 /MIC ratio) was the PK-PD measure most predictive of survival ( R 2 = 0.96). The 50% effective dose (ED 50 ) and the ED 90 and ED 99 corresponded to AUC 0-24 /MIC ratios of 11.5, 15.8, and 30, respectively, where the maximum effect was 97% survival. Simulation results indicate that a daily gatifloxacin dose of 400 mg for adults and 10 mg/kg of body weight for children gives a 100% probability of attaining the PK-PD target (ED 99 ). Sensitivity analyses suggest that the probability of PK-PD target attainment in adults and children is not affected by increases in MICs for strains of B. anthracis to levels as high as 0.5 mg/liter.Keywords
This publication has 20 references indexed in Scilit:
- Pharmacokinetics and pharmacodynamics of gatifloxacin in children with recurrent otitis media: application of sparse sampling in clinical developmentDiagnostic Microbiology and Infectious Disease, 2007
- Determination of Antibiotic Efficacy against Bacillus anthracis in a Mouse Aerosol Challenge ModelAntimicrobial Agents and Chemotherapy, 2007
- Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice AnymoreClinical Infectious Diseases, 2007
- Effective Antimicrobial Regimens for Use in Humans for Therapy ofBacillus anthracisInfections and Postexposure ProphylaxisAntimicrobial Agents and Chemotherapy, 2005
- Use of Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Phase 2 and 3 Dosing Strategies for DoripenemAntimicrobial Agents and Chemotherapy, 2005
- Clinical Pharmacodynamics of Linezolid in Seriously Ill Patients Treated in a Compassionate Use ProgrammeClinical Pharmacokinetics, 2003
- In Vivo Pharmacodynamics of a New Oxazolidinone (Linezolid)Antimicrobial Agents and Chemotherapy, 2002
- Pharmacodynamics of the New Fluoroquinolone Gatifloxacin in Murine Thigh and Lung Infection ModelsAntimicrobial Agents and Chemotherapy, 2002
- Rational Dose Selection for a Nonnucleoside Reverse Transcriptase Inhibitor through Use of Population Pharmacokinetic Modeling and Monte Carlo SimulationAntimicrobial Agents and Chemotherapy, 2002
- A new look at the statistical model identificationIEEE Transactions on Automatic Control, 1974